Mariner
RYTM icon

Mariner’s Rhythm Pharmaceuticals RYTM Stock Holding History

Mariner’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,597
Closed -$363K – 3774
2025
Q3 		$363K Sell
3,597
-724
-17% -$67.2K ﹤0.01% 2659
2025
Q2 		$273K Sell
4,321
-264
-6% -$16.2K ﹤0.01% 2797
2025
Q1 		$243K Buy
4,585
+60
+1% +$3.33K ﹤0.01% 2832
2024
Q4 		$254K Buy
+4,525
New +$250K ﹤0.01% 2783

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mariner's RYTM Position: Q4 2025 in Review

Mariner sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 3,597 shares — an estimated $363K sold.

Mariner first reported a position in RYTM in Q4 2024 and held it in 4 quarters. The position peaked at $363K in Q3 2025. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • Mariner reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mariner sold 3,597 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $363K.
  • Mariner first reported a position in Rhythm Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Mariner's Rhythm Pharmaceuticals position peaked at $363K in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.